{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a
to a specific field?
Class (Stereo):
CHEMICAL (MIXED)
Iotriside is triiodoisophthalic acid derivative patented by Schering A.-G. as nonionic contrast media.
Status:
Investigational
Source:
NCT00446979: Phase 1 Interventional Completed HIV Infections
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
N-(4-Chloro-3-((3-Methyl-2-Butenyl)Oxy)Phenyl)-2-Methyl-3-Furancarbothioamide (also known as UC-781) is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor patented by Uniroyal Chemical Company, Inc. for prevention of HIV transmission. UC-781 is a potent inhibitor of reverse transcriptase-dependent pyrophosphorolysis, and purportedly restores the chain-terminating activity of zidovudine (AZT) against AZT-resistant virus. In clinical trials single and 7-day topical rectal exposure of UC-781 was safe with no significant adverse events, no detected UC-781 plasma drug levels, no significant mucosal changes, and high participant acceptability. Ex vivo biopsy infections demonstrated marked suppression of HIV infectibility, identifying a potential early biomarker of efficacy.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
FENLEUTON is a potent, reversible and selective inhibitor of 5-lipoxygenase with IC50 values ranging from 80 to 1100 nM. It was studied for potential use in veterinary medicine to treat chronic obstructive pulmonary disease in horses.
Class (Stereo):
CHEMICAL (RACEMIC)
Trimeperidine (promedol) is the earliest and mostly studied opioid analgesic. Trimeperidine stimulates opioid receptors in the central nervous system. Compared with morphine, it has a weaker and shorter analgesic effect, less affects the respiratory, vomiting and vagal centers, does not cause smooth muscle spasm (except for the myometrium), and has a moderate antispasmodic and hypnotic effect. It is used to treat severe pain syndrome, acute left ventricular failure, pulmonary edema, cardiogenic shock, preparation for surgery, childbirth, high fever, post-transfusion complications, poisoning with atropine, barbiturates, barium, gasoline, boric acid, strong acids, carbon monoxide, turpentine, formalin, formalin. It has several side effects. Administration of this substance is associated with the development of life-threatening conditions accompanied by the suppression of respiration center. Analgesic trimeperidine (promedol) was included into the health care kits by various Ministries of the Russian Federation at different times.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Dazoxiben is a selective inhibitor of thromboxane synthetase (IC50 3 nM), an enzyme that converts the endo-peroxide PGH2 into thromboxane A2, which is a potent vasoconstrictor and platelet aggregating agent. Dazoxiben has demonstrated efficacy in some clinical trial for the treatment of Raynaud's syndrome, an ischaemic condition manifested by the pallor of affected digits. In subsequent studies, however, no significant effect of dazoxiben was found. Dazoxiben was also evaluated in patients with sepsis, adult respiratory distress syndrome, stable angina, and other conditions.
Class (Stereo):
CHEMICAL (ACHIRAL)
Intriptyline is a dibenzocycloheptene derivative and mixed monoamine reuptake inhibitor patented by Laboratoires du Docteur Jacques Auclair as tricyclic antidepressant.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Pirlindole is a selective and reversible inhibitor of monoamine oxidase (MAO) subtype A (MAO-A). It exerts an inhibitory effect on noradrenaline and 5-hydroxytryptamine reuptakes. It has no effect on the dopaminergic and cholinergic systems. It has only a low potential for amplifying tyramine and noradrenaline pressor effect, which makes one expect that it will not be at the basis of a ‘cheese effect’. Pirlindole was approved in some European and non-European countries for the treatment of depression. The antidepressant efficacy and safety of pirlindole have been demonstrated in a number of placebo- and active comparator-controlled studies and are supported by many years of clinical experience in the treatment of depression. The drug's efficacy and safety have also been demonstrated in the treatment of fibromyalgia syndrome. Pirlindole has a favorable tolerability profile, with no deleterious effect on cardiovascular dynamics. The effect of pirlindole on sensorimotor performance relevant to driving a motor vehicle is similar to that of placebo, as pirlindole appears to have an activating rather than a sedating antidepressant profile. Pirlindole prevented qualitative alteration (transformation) in the catalytic activity of membrane-bound type A monoamine oxidases (MAO-A), pathogenetically important for the development of the audiogenic seizures.
Class (Stereo):
CHEMICAL (ACHIRAL)
Dametralast is an antihistamine agent. Bronchodilator action of dametralast was demonstrated on the isolated trachea of guinea pigs. Dametralast prevents bronchospasm in anesthetized guinea-pigs, protects mice from anaphylactic shock induced by injection of bovine albumin, and has a protective effect in passive cutaneous anaphylaxis test in rats. Investigations into the mechanism of action have shown that the drug was ineffective on the synthesis of cyclooxygenase products from arachidonic acid. Dametralast inhibited cAMP phosphodiesterase (PDE) but this inhibition does not seem to be involved in their anti-inflammatory activity. In clinical tests dametralast was well tolerated; functional respiratory exploration determinations provided the same bronchodilator effect found in animals. A favorable effect was noted in asthmatic subjects and in subjects suffering from respiratory insufficiency.
Class (Stereo):
CHEMICAL (ACHIRAL)
Dazoquinast is an imidazoquinoxaline derivative with antiallergic properties, developed by the British company Roussel Laboratories Ltd. Dazoquinast inhibited the IgE-mediated passive cutaneous anaphylaxis in rats passively sensitized to ovalbumen after intravenous and oral administration with ED50s of 0.073 and 0.13 mg/kg respectively.
